valeant

Have any reps left Alamo (under the Valeant and Bausch contract) and you did NOT get paid your final commissions because you were not actively employed at the time of payout? They snuck this little caveat in our IC plans starting in 2018 if you didn’t notice. I have great news!

Would the government be interested to know that Prugen Executives actually run GenRx? Prugen installed a figurehead who does exactly what Sean Lonergan, Prugen CEO, and Kevin Kriel, Prugen EVP, instruct. Prugen's EVP is sleeping with GenRx's former VP of Operations, who is now Prugen's VP of...

Way to go B+L! 20% market share for Lumify in only a couple of months! https://www.cnbc.com/video/2018/09/17/bausch-health-ceo-joe-papa-talks-rd-companys-turnaround.html

Valeant reported revenue of $1.99 billion for the first quarter of 2018, down 5% YoY Organic revenue growth was 2%, driven by growth in the Salix business and the Bausch + Lomb/International segment. Net loss of $2.69 billion, primarily due to a decrease in the benefit from income taxes and...

https://news.alphastreet.com/benefiting-from-tax-gains-valeant-pharma-swings-to-profit-in-q4/ The company now forecasts full year revenues below its previous expectation

Can't wait to hear all about your innovative products for dermatology.

Valeant said it will sell Sprout, the subsidiary that produces Addyi-the female libido pill, to a former shareholder of Sprout in exchange for a 6% royalty on global sales of Addyi. The sale is expected to close before the end of 2017. Addyi is the only approved and commercialized product of...

Valeant posted a quarterly profit helped by the strong performance of its Bausch and Lomb Business. Net income attributable to Valeant rose to $1.30Bil, or $3.69 per share, during the quarter , compared with a loss of $1.22Bil, or $3.49 per share, a year earlier. Total revenue fell 10.5% to...

Valeant posted a quarterly profit helped by the strong performance of its Bausch and Lomb Business. Net income attributable to Valeant rose to $1.30Bil, or $3.69 per share, during the quarter , compared with a loss of $1.22Bil, or $3.49 per share, a year earlier. Total revenue fell 10.5% to...

Is Valeant is making a good progress towards paying down a huge debt of $5Bil Debt by Feb. 2018? Take a look at their progress. http://alph.st/bd2f993b

Valeant completed the sale of its iNova Pharmaceuticals business for $930MM in cash. The pharma company intends to use the net proceeds from the sale to repay term loan debt under its Senior Credit Facility. http://alph.st/bf137c6c

Valeant cut its full-year revenue forecast to $8.70 - $8.90 billion from $8.90 - $9.10 billion. Revenue during the quarter fell 8 percent to $2.23-billion in the second quarter ended June 30. This was due to declines in volume and pricing of its generic and neurology products. Net loss narrowed...

Valeant has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility...

Valeant could be back to growing again. The company pays down $811million of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC.

Shock Exchange from Seeking Alpha says Valeant is "Pharma's Bernie Madoff" ---> https://seekingalpha.com/article/4078319-valeant-pharmas-bernie-madoff (1) Madoff was insolvent and his NAV was opaque. Valeant is insolvent by $8B and our book value is opaque. (2) Valeant has $35 billion in...

Ok, let's talk about salaries and bonuses across EU & Asia... What is average salaries and bonuses in EU countries (including Russia and CIS) & Asia, and will they be payed this year?